A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)

Exclusion Criteria

• •Pregnant, breastfeeding, or women not taking contraception
• •Patients \< 40kg
• •Treatment with any investigational agent within 30 days of screening
• •Recent history of drug or alcohol abuse
• •Atopic dermatitis or other skin disease associated with pruritus
• •Clinically relevant major systemic disease (making interpretation of the study results difficult)
• •Previously treated with omalizumab (\< 12 months since last injection)
• •Patients may not take during treatment period or have been taking within the past 3 months any of the following medications/treatments: regular (daily/every other day) hydroxychloroquine, methotrexate, cyclosporine, cyclophosphamide, IVIG, or plasmapheresis
• •Patients may not have been taking doxepin within the past 6 weeks regular (daily/every other day).